Restless Legs Syndrome: Iron First and the Dopamine-Agonist Caution
Restless legs syndrome: why current guidance checks iron and ferritin first, favors gabapentinoids, and treats dopamine agonists with caution.
Health & Evidence Library
Evidence guides on neurologic symptoms, cognition, healthy aging, sleep, and the decisions that connect function with safety.
47 guides · Page 1 of 1
Restless legs syndrome: why current guidance checks iron and ferritin first, favors gabapentinoids, and treats dopamine agonists with caution.
Tension-type, migraine, and cluster headaches differ in pain, timing, and triggers. Learn how to tell them apart and which red flags need urgent care.
Why the room spins when you lie down is often BPPV. How vertigo differs from lightheadedness, and how the Dix-Hallpike and Epley maneuvers work.
How deprescribing and a structured polypharmacy review work in older adults, when to stop medicines safely, and how to spot drug-caused symptoms.
Stroke benefit generally falls with treatment delay, but eligibility depends on stroke type, imaging, severity, timing, and individual risk.
Trials from 2022 onward showed that selected large-core strokes can benefit from thrombectomy, informing expanded 2026 stroke guidance.
VO2max strongly predicts mortality, but cohort studies cannot prove that raising one person's score will extend that person's life.
The 12 hallmarks of aging organize molecular change, but they are not a longevity score. Learn what human trials, aging clocks, and geroscience can show.
Genetics, biomarkers, failed trials, lecanemab, and donanemab have all tested the amyloid hypothesis. Here is what the evidence supports and what remains open.
Multiple stroke trials found tenecteplase noninferior to alteplase. Learn what the margins, outcomes, populations, doses, and safety results actually establish.
Rank practical sleep habits by mechanism, test changes realistically, and know when sleep hygiene is not enough to treat a sleep disorder.
Snoring is only one clue. Learn which sleep-apnea signs, risk patterns, daytime effects, and test results deserve clinical evaluation.
A practical plan for shift-work sleep, light, naps, caffeine, commuting, rotations, fatigue reporting, and when symptoms need care.
Human senolytic trials remain early. Learn what cellular senescence is, what small trials show, and why animal results do not prove healthier aging.
Learn how sarcopenia definitions combine muscle strength, muscle quantity, and physical performance, and why thresholds differ across groups.
A critical review of human rapamycin and rapalog trials for aging-related outcomes, including PEARL, immune studies, safety limits, and unanswered questions.
Why CBT-I is first-line care for chronic insomnia, what it contains, where sleep habits fit, and when medicines or testing may help.
Evidence-based sleep ranges by age, why individual need varies, and how duration, quality, timing, regularity, and function fit together.
What the 2024 American Headache Society position statement changed about CGRP migraine prevention, and the evidence that moved these drugs to first line.
How the 2024 McDonald criteria diagnose MS earlier using the optic nerve, the central vein sign, and kappa free light chains, with new safeguards against error.
Why the AAN found several drug classes work about equally for painful diabetic neuropathy, and how OPTION-DM confirmed it head to head.
Why IARC calls night shift work "probably carcinogenic," what Group 2A does and does not mean, and why the human cancer evidence is graded as limited.
A plain-language guide to what nerve conduction studies and EMG measure, why they favor specificity, and how sensitivity and their limits shape a diagnosis.
NR and NMN reliably raise blood NAD+ in trials, but no controlled study proves they slow aging, and legal status says nothing about benefit.
What the reperfusion and outcome evidence says about mobile stroke units, why the 2026 guideline endorses them, and the cost and access questions left open.
A plain-language guide to the CDR-SB endpoint, lecanemab's 0.45-point result, and why "clinically meaningful" is still debated.
How the DAWN and DEFUSE 3 trials used perfusion imaging to select late stroke patients for thrombectomy, and why the criteria are narrow.
The 0.8 g/kg RDA versus expert proposals of 1.0 to 1.2 g/kg for older adults, and what the evidence does and does not settle.
How a single neuropeptide, CGRP, moved from a lab curiosity to a validated migraine drug target, and why two different medicine classes now confirm the biology.
Lifespan counts your years; healthspan counts the good ones. Why compressing illness into a short window matters more than any longevity product.
Handgrip strength predicts death more strongly than systolic blood pressure, but it reads underlying health rather than driving it. Here is how to use it well.
The ESETT trial showed three second-line seizure drugs work about equally, and a null comparative result turns out to be genuinely useful.
How RESPECT, CLOSE, REDUCE, and the RoPE score frame who benefits from PFO closure after an unexplained stroke under age 60.
A plain-language look at the first FDA-cleared Alzheimer's blood test and the 2025 guideline, including who it is for and where it falls short.
What epigenetic clocks measure, how they are validated, and why a single biological-age result is not a personal lifespan verdict.
Why corticosteroids earn a strong recommendation for Bell palsy while antivirals do not, and how to read the guideline behind both verdicts.
What CREST-2 means for symptom-free carotid narrowing, and why the trial's low event rates matter more than which procedure "won.
How pooled POINT and CHANCE data set the 21-day window for aspirin plus clopidogrel after minor stroke, and why bleeding risk drew the line
What ARIA edema and hemorrhage mean with lecanemab and donanemab, and how titration, APOE4 testing, and MRI monitoring lower the risk.
Which vaccines matter more with age? A calm guide to shingles, pneumococcal, enhanced flu, and RSV shots for older adults, and how to read the adult schedule.
Exercise and protein for older adults rebuild muscle, cut fall risk, and protect independence. Here are the evidence-based numbers behind the guidelines.
When does polypharmacy in older adults become a problem? A plain guide to the risks of too many medicines, the Beers Criteria, and safe deprescribing.
Normal aging vs concerning memory changes: how to tell everyday forgetfulness from dementia warning signs, what mimics dementia, and when to see a doctor.
Healthy aging is less about genetics than a few daily habits. See what the evidence says about movement, strength, sleep, connection, and prevention.
Falls prevention for older adults works best with balance and strength exercise, a medication review, up-to-date vision, and home safety. Here is the evidence.
Age-related hearing and vision changes touch falls, driving, mood, and memory. Here is what the evidence shows and the practical steps that help.
Advance care planning explained in plain language: what it is, how a healthcare proxy and living will differ, and how to start the conversation with family.